A phase II study of glembatumumab vedotin for metastatic uveal melanoma

Authors

Merve Hasanov, The University of Texas MD Anderson Cancer Center
Matthew J Rioth, University of Colorado
Kari Kendra, The Ohio State University Comprehensive Cancer Center
Leonel Hernandez-Aya, Washington University School of Medicine in St. Louis
Richard W Joseph, Mayo Clinic Hospital
Stephen Williamson, University of Kansas Medical Center
Sunandana Chandra, Northwestern University
Keisuke Shirai, Dartmouth-Hitchcock Medical Center
Christopher D Turner, Blueprint Medicines
Karl Lewis, University of Colorado
Elizabeth Crowley, Celldex Therapeutics, Inc.
Jeffrey Moscow, Cancer Therapy Evaluation Program National Institute of Health (CTEP)
Brett Carter, The University of Texas MD Anderson Cancer Center
Sapna Patel, The University of Texas MD Anderson Cancer Center

Journal

Cancers (Basel)

Publication Date

2020

Volume

12

Issue

8

First Page

2270

Document Type

Open Access Publication

DOI

10.3390/cancers12082270

Rights and Permissions

Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, Crowley E, Moscow J, Carter B, Patel S. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. Cancers (Basel). 2020 Aug 13;12(8):2270. doi: 10.3390/cancers12082270.

Recommended Citation

Hasanov, Merve; Rioth, Matthew J; Kendra, Kari; Hernandez-Aya, Leonel; Joseph, Richard W; Williamson, Stephen; Chandra, Sunandana; Shirai, Keisuke; Turner, Christopher D; Lewis, Karl; Crowley, Elizabeth; Moscow, Jeffrey; Carter, Brett; and Patel, Sapna, "A phase II study of glembatumumab vedotin for metastatic uveal melanoma." Cancers (Basel). 12, 8. 2270 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9516